US hospital sales of Novo Nordisk's hemophilia drug dropped in December

In December, Novo Nordisk's hemophilia treatment Novoseven sold less to US hospitals, shows data collected by Symphony Health Solutions.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde

Hospitals sales from Novo Nordisk's hemophilia drug Novoseven dropped 4.3 percent in December when calculated over a four-month period and compared with a similar period leading up to November, which data from Symphony Health Solutions shows, according to Bloomberg News.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading